aNK (NK-92) + aNK (NK-92) + N-803
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 24/100
24
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Stage IIIB Merkel Cell Carcinoma
Conditions
Stage IIIB Merkel Cell Carcinoma, Stage IV Merkel Cell Carcinoma
Trial Timeline
Sep 24, 2015 → Mar 19, 2018
NCT ID
NCT02465957About aNK (NK-92) + aNK (NK-92) + N-803
aNK (NK-92) + aNK (NK-92) + N-803 is a phase 2 stage product being developed by ImmunityBio for Stage IIIB Merkel Cell Carcinoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT02465957. Target conditions include Stage IIIB Merkel Cell Carcinoma, Stage IV Merkel Cell Carcinoma.
What happened to similar drugs?
20 of 20 similar drugs in Stage IIIB Merkel Cell Carcinoma were approved
Approved (20) Terminated (2) Active (0)
✅Henagliflozin 5 mg Group + Henagliflozin 10 mg Group + Conventional therapy groupJiangsu Hengrui MedicineApproved
Hype Score Breakdown
Clinical
12
Activity
0
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02465957 | Phase 2 | Terminated |
Competing Products
20 competing products in Stage IIIB Merkel Cell Carcinoma